{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"11.2","value":"4.2"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"21.0","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Presence of CIN"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"33.1","value":"8.5"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"28.0","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Absence of CIN"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"11.2","value":"3.0"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"21.0","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Presence of NE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"33.1","value":"8.2"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"28.0","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"Absence of NE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Circulating tumor cell (CTC) counts were considered as biomarker in a liquid biopsy. rPFS in participants with presence and absence of subtypes of CTC biomarker i.e. chromosomal instability (CIN) and neuroendocrine (NE) was reported in this outcome measure. rPFS was defined as: time (in months) from randomization to the first occurrence of any one of following: radiological tumor progressions (RECIST1.1), progression of bone lesions (PCWG2 criteria) or death due to any cause. Progression (RECIST1.1): at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with \\>= 2 new lesions compared to Baseline observed \\<12 weeks from randomization and confirmed by a second bone scan performed \\>=6 weeks later; first bone scan with \\>=2 new lesions compared to Baseline observed \\>=12 weeks from randomization and new lesions were verified on next bone scan \\>= 6 weeks later.","dispersionType":"Full Range","groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"OG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks)","id":"OG001","title":"Abiraterone Acetate or Enzalutamide"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on subset of participants analyzed according to the treatment group allocated by randomization with evaluable samples.","reportingStatus":"POSTED","timeFrame":"From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)","title":"Radiographic Progression-Free Survival (rPFS) in Participants With Presence and Absence of Biomarker","type":"SECONDARY","unitOfMeasure":"months"}